Nabsys raises $21 million equity round led by Hitachi High-Technologies

Nabsys, the pioneer in high-definition genome mapping, announced that it has closed on a $21 million equity round led by Hitachi High-Technologies.

Nabsys will use the funding to finalize product development and support global commercial launch of their HD-Mapping™ whole-genome electronic mapping platform.

HD-Mapping has applications in a wide variety of key research applications, including de novo assembly, structural variant analysis, metagenome characterization, and strain identification, as well as in next-generation cytogenetics. Nabsys electronic mapping enables routine, scalable analysis of genomic structural variation.

Mr. Tsuyoshi Ogino, General Manager, Innovation Division at Hitachi High-Technologies said, “There is a strong need for accurate, robust, and scalable genomic structural analysis for cytogenetic, cancer, and infectious disease research. Hitachi High-Technologies determined that the Nabsys HD-Mapping approach effectively supports this need. The company is also a strong fit with our strategy for continued advanced R&D with strategic investments in life sciences.”

This investment round will help Nabsys fulfill its mission to make the analysis of large- and intermediate-scale genomic variation as routine, accurate, and cost-effective as the analysis of single-nucleotide variation,” said Barrett Bready, M.D., Founder and CEO at Nabsys.

About Nabsys:
Nabsys is the in high-definition electronic genome mapping. Nabsys uses proprietary electronic nanochannel detectors to analyze long DNA molecules at high velocity. Nabsys HD-Mapping™ whole genome maps with sub-diffraction-limit resolution, provide compelling advantages for the analysis of genomic structural variation, genome assembly, and high-specificity strain identification.


Related presentations

Liked this post?

Share it on your social networks